TY - JOUR
T1 - Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis
T2 - Multi-centered prospective observational study
AU - Lee, Byung H.
AU - Inui, Daisuke
AU - Suh, Gee Y.
AU - Kim, Jae Y.
AU - Kwon, Jae Y.
AU - Park, Jisook
AU - Tada, Keiichi
AU - Tanaka, Keiji
AU - Ietsugu, Kenichi
AU - Uehara, Kenji
AU - Dote, Kentaro
AU - Tajimi, Kimitaka
AU - Morita, Kiyoshi
AU - Matsuo, Koichi
AU - Hoshino, Koji
AU - Hosokawa, Koji
AU - Lee, Kook H.
AU - Lee, Kyoung M.
AU - Takatori, Makoto
AU - Nishimura, Masaji
AU - Sanui, Masamitsu
AU - Ito, Masanori
AU - Egi, Moritoki
AU - Honda, Naofumi
AU - Okayama, Naoko
AU - Shime, Nobuaki
AU - Tsuruta, Ryosuke
AU - Nogami, Satoshi
AU - Yoon, Seok Hwa
AU - Fujitani, Shigeki
AU - Koh, Shin O.
AU - Takeda, Shinhiro
AU - Saito, Shinsuke
AU - Hong, Sung J.
AU - Yamamoto, Takeshi
AU - Yokoyama, Takeshi
AU - Yamaguchi, Takuhiro
AU - Nishiyama, Tomoki
AU - Igarashi, Toshiko
AU - Kakihana, Yasuyuki
AU - Koh, Younsuck
PY - 2012/2/28
Y1 - 2012/2/28
N2 - Introduction: Fever is frequently observed in critically ill patients. An independent association of fever with increased mortality has been observed in non-neurological critically ill patients with mixed febrile etiology. The association of fever and antipyretics with mortality, however, may be different between infective and non-infective illness.Methods: We designed a prospective observational study to investigate the independent association of fever and the use of antipyretic treatments with mortality in critically ill patients with and without sepsis. We included 1,425 consecutive adult critically ill patients (without neurological injury) requiring > 48 hours intensive care admitted in 25 ICUs. We recorded four-hourly body temperature and all antipyretic treatments until ICU discharge or 28 days after ICU admission, whichever occurred first. For septic and non-septic patients, we separately assessed the association of maximum body temperature during ICU stay (MAX ICU) and the use of antipyretic treatments with 28-day mortality.Results: We recorded body temperature 63,441 times. Antipyretic treatment was given 4,863 times to 737 patients (51.7%). We found that treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen independently increased 28-day mortality for septic patients (adjusted odds ratio: NSAIDs: 2.61, P = 0.028, acetaminophen: 2.05, P = 0.01), but not for non-septic patients (adjusted odds ratio: NSAIDs: 0.22, P = 0.15, acetaminophen: 0.58, P = 0.63). Application of physical cooling did not associate with mortality in either group. Relative to the reference range (MAX ICU 36.5°C to 37.4°C), MAX ICU ≥ 39.5°C increased risk of 28-day mortality in septic patients (adjusted odds ratio 8.14, P = 0.01), but not in non-septic patients (adjusted odds ratio 0.47, P = 0.11).Conclusions: In non-septic patients, high fever (≥ 39.5°C) independently associated with mortality, without association of administration of NSAIDs or acetaminophen with mortality. In contrast, in septic patients, administration of NSAIDs or acetaminophen independently associated with 28-day mortality, without association of fever with mortality. These findings suggest that fever and antipyretics may have different biological or clinical or both implications for patients with and without sepsis.Trial registration: ClinicalTrials.gov: NCT00940654.
AB - Introduction: Fever is frequently observed in critically ill patients. An independent association of fever with increased mortality has been observed in non-neurological critically ill patients with mixed febrile etiology. The association of fever and antipyretics with mortality, however, may be different between infective and non-infective illness.Methods: We designed a prospective observational study to investigate the independent association of fever and the use of antipyretic treatments with mortality in critically ill patients with and without sepsis. We included 1,425 consecutive adult critically ill patients (without neurological injury) requiring > 48 hours intensive care admitted in 25 ICUs. We recorded four-hourly body temperature and all antipyretic treatments until ICU discharge or 28 days after ICU admission, whichever occurred first. For septic and non-septic patients, we separately assessed the association of maximum body temperature during ICU stay (MAX ICU) and the use of antipyretic treatments with 28-day mortality.Results: We recorded body temperature 63,441 times. Antipyretic treatment was given 4,863 times to 737 patients (51.7%). We found that treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen independently increased 28-day mortality for septic patients (adjusted odds ratio: NSAIDs: 2.61, P = 0.028, acetaminophen: 2.05, P = 0.01), but not for non-septic patients (adjusted odds ratio: NSAIDs: 0.22, P = 0.15, acetaminophen: 0.58, P = 0.63). Application of physical cooling did not associate with mortality in either group. Relative to the reference range (MAX ICU 36.5°C to 37.4°C), MAX ICU ≥ 39.5°C increased risk of 28-day mortality in septic patients (adjusted odds ratio 8.14, P = 0.01), but not in non-septic patients (adjusted odds ratio 0.47, P = 0.11).Conclusions: In non-septic patients, high fever (≥ 39.5°C) independently associated with mortality, without association of administration of NSAIDs or acetaminophen with mortality. In contrast, in septic patients, administration of NSAIDs or acetaminophen independently associated with 28-day mortality, without association of fever with mortality. These findings suggest that fever and antipyretics may have different biological or clinical or both implications for patients with and without sepsis.Trial registration: ClinicalTrials.gov: NCT00940654.
UR - http://www.scopus.com/inward/record.url?scp=84862821595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862821595&partnerID=8YFLogxK
U2 - 10.1186/cc11211
DO - 10.1186/cc11211
M3 - Article
C2 - 22373120
AN - SCOPUS:84862821595
SN - 1364-8535
VL - 16
JO - Critical Care
JF - Critical Care
IS - 1
M1 - R33
ER -